Loading organizations...
§ Private Profile · Cambridge, MA, USA
Ring Therapeutics is a technology company.
Ring Therapeutics develops programmable medicines utilizing anellovirus vectors. The company engineers these abundant commensal viruses to safely deliver diverse therapeutic modalities to specific cells and tissues. Their platform exploits anelloviruses' unique properties and tissue tropisms, establishing a foundation for gene therapy.
Ring Therapeutics was founded in 2017 within Flagship Labs, the innovation foundry of Flagship Pioneering. Founders Avak Kahvejian, PhD, Erica Weinstein, PhD, and Noubar Afeyan, PhD, explored commensal virome. They identified anelloviruses, previously deemed non-pathogenic, realizing their inherent safety and ubiquity could enable therapeutic delivery, prompting engineering into novel vectors.
The company focuses on patients needing advanced genetic therapies. Ring's vision centers on transforming commensal viruses into life-saving treatments. Harnessing anelloviruses, the company aims to establish a broad, programmable platform, delivering diverse payloads and expanding genetic medicine's frontiers.
Ring Therapeutics has raised $207.0M across 2 funding rounds.
Ring Therapeutics has raised $207.0M in total across 2 funding rounds.
Ring Therapeutics has raised $207.0M across 2 funding rounds. Most recently, it raised $87.0M Series C in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $87M Series C | Flagship Pioneering, Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Invus, Kyowa Kirin, Partners Investment, T. Rowe Price Associates, UPMC Enterprises | — | Announced |
| Jul 1, 2021 | $120M Series B | — | Flagship Pioneering, Altitude Life Science Ventures, Invus, Partners Investment, T. Rowe Price Associates, UPMC Enterprises | Announced |
Ring Therapeutics is a biotechnology company developing Anellovectors™, a novel gene therapy platform based on anelloviruses from the human commensal virome. These engineered viral vectors aim to deliver diverse genetic medicines to target tissues with advantages like immune evasion, tissue tropism, payload versatility, potency, and potential redosability, addressing limitations in current gene therapies.[2][5] The company serves patients with significant unmet needs in genetic diseases by creating safer, more effective, and repeatable therapies, with its Anellogy™ platform driving programmable medicines through viral discovery, synthesis, and engineering.[1][2]
Founded in 2017 and headquartered in Cambridge, MA, Ring has shown growth momentum through platform advancements, including presentations on its AnelloBricks® biomanufacturing platform at the 2025 American Society of Gene & Cell Therapy Conference, alongside leadership transitions like Chris McNulty as Interim CEO.[2][4]
Ring Therapeutics originated at Flagship Pioneering's Flagship Labs, an innovation foundry, where a founding team including Avak Kahvejian, PhD; Erica Weinstein, PhD; and Noubar Afeyan, PhD, explored the human commensal virome.[1] They identified anelloviruses—previously dismissed as non-pathogenic from early 2000s transfusion samples—noting their safety, ubiquity, and transmissibility as ideal for gene therapy vectors.[1] After mining genomic data, synthesizing, and engineering these viruses with successful experimental validation, Flagship launched Ring Therapeutics in 2017.[1]
Flagship Pioneering, active since 2000, has originated over 100 ventures with $100B+ in value, including Moderna and Sana Biotechnology, providing Ring with deep bioplatform expertise.[1] Early traction came from proving the platform's potential for broad programmable medicines.[1]
Ring stands out in gene therapy through its exploitation of anelloviruses' natural evolution-honed traits:
These features position Anellovectors™ as the first potentially redosable and targetable gene therapy platform.[5]
Ring rides the gene therapy expansion trend, leveraging the commensal virome to overcome key hurdles like immunogenicity, limited tropism, and single-dose constraints in AAV-based treatments.[2][5] Timing aligns with maturing genetic medicine demand, post-Moderna's mRNA success (a Flagship alum), and rising vectorized antibody innovations noted in 2025 market research.[1][4] Favorable forces include genomic data abundance for viral mining and biomanufacturing advances amid a push for tissue-specific, repeatable therapies.[1][4]
As a Flagship Pioneering spinout, Ring influences the ecosystem by pioneering virome-derived platforms, potentially accelerating Flagship's $100B+ portfolio impact and inspiring virome exploration in biotech.[1]
Ring's trajectory points to clinical milestones, with AnelloBricks® data signaling manufacturing readiness and leadership like CTO Konstantin Konstantinov driving execution.[4] Trends like vectorized therapies and in vivo expression (per 2025 reports) will propel Anellovectors™ toward IND filings and partnerships.[4] Influence may grow via Flagship's network, evolving into a multi-product leader in redosable gene therapies and reshaping virome utilization in medicine—echoing its origins in overlooked transfusion viruses now powering a new programmable era.[1][2]
Ring Therapeutics has raised $207.0M in total across 2 funding rounds.
Ring Therapeutics's investors include Flagship Pioneering, Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Invus, Kyowa Kirin, Partners Investment, T. Rowe Price Associates, UPMC Enterprises.